<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05614934</url>
  </required_header>
  <id_info>
    <org_study_id>0107175</org_study_id>
    <nct_id>NCT05614934</nct_id>
  </id_info>
  <brief_title>Vonoprazan-based Therapy Versus Standard Regimen for Helicobacter Pylori Infection Management</brief_title>
  <official_title>Vonoprazan-based Therapy Versus Standard Regimen for Helicobacter Pylori Infection Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Appropriately, half of the global population is infected with H. pylori, and it is now&#xD;
      recognized that it causes at least 95% of all gastric cancers. Currently, the main challenge&#xD;
      in the field of H. pylori infection is the rapidly increasing antibiotic resistance&#xD;
      worldwide, which is causing a decline in the effectiveness of currently available eradication&#xD;
      regimens.&#xD;
&#xD;
      The aim of the study is to assess the safety and efficacy of different H. pylori&#xD;
      vonoprazan-based regimens compared to the commonly used standard triple therapy composed of&#xD;
      Clarithromycin, Amoxicillin, and Proton pump inhibitor to eradicate H. pylori infection in&#xD;
      treatment-naive patients through the determination of each regimen eradication rate and&#xD;
      reported safety profile&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Ethical committee approval is obtained from Ethics committee of Faculty of Medicine,&#xD;
           Alexandria University.&#xD;
&#xD;
        2. All participants should agree to take part in this clinical study and will provide&#xD;
           informed consent.&#xD;
&#xD;
        3. Patients with suspected H. pylori infection are recruited from Alexandria University&#xD;
           out-patient clinics&#xD;
&#xD;
        4. Participants' demographic data, Full medical and medication history, and detailed&#xD;
           clinical presentation is documented&#xD;
&#xD;
        5. Participants are tested for H. pylori infection using rapid H. pylori stool antigen test&#xD;
           device&#xD;
&#xD;
        6. Negative subjects are excluded while positive patients are randomly allocated to 3&#xD;
           groups of different H. pylori regimens (Standard triple, Vonoprazan dual, and Vonoprazan&#xD;
           triple)&#xD;
&#xD;
        7. Following up treatment side effects while taking the medications.&#xD;
&#xD;
        8. Assessing regimens effectiveness through patient retesting at least 1 month after&#xD;
           treatment completion.&#xD;
&#xD;
        9. Assessing patient compliance to different regimens during the final visit.&#xD;
&#xD;
       10. Statistical tests appropriate to the study design will be conducted to evaluate the&#xD;
           significance of the results.&#xD;
&#xD;
       11. Results, conclusion, discussion and recommendations will be given.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2022</start_date>
  <completion_date type="Anticipated">March 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-labeled, prospective, three-arm, parallel-group, non-placebo Randomized controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the eradication rates for each regimen</measure>
    <time_frame>1.5 month</time_frame>
    <description>Percentage eradication in each group is calculated by intention-to-treat analysis or per-protocol analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of number of compliant participants to each regimen</measure>
    <time_frame>1.5 month</time_frame>
    <description>Adherence to therapies is determined through pill count in medication boxes In addition to reviewing a daily medication schedule filled by the participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of number of participants with treatment related adverse events</measure>
    <time_frame>2 weeks</time_frame>
    <description>Patients will be contacted on a regular basis to monitor any reported adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>S3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard clarithromycin triple</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vonoprazan triple</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vonoprazan dual</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard Clarithromycin triple therapy</intervention_name>
    <description>Oral administration of proton pump inhibitor standard or double dose twice daily, clarithromycin 500 mg twice daily and, Amoxicillin1g twice daily for 14 days</description>
    <arm_group_label>S3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vonoprazan triple therapy</intervention_name>
    <description>Oral administration of Vonoprazan 20mg twice daily, clarithromycin 500 mg twice daily, and, Amoxicillin1g twice daily for 14 days</description>
    <arm_group_label>V3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vonoprazan dual therapy</intervention_name>
    <description>Oral administration of Vonoprazan 20mg twice daily and, Amoxicillin1g three times daily for 14 days</description>
    <arm_group_label>V2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with positive stool antigen test result for H. pylori&#xD;
&#xD;
          -  Patients recently diagnosed with H. pylori infection and did not receive any treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients sensitive to any of the regimens' components&#xD;
&#xD;
          -  Patients who had received a previous eradication therapy and still show positive test&#xD;
             results&#xD;
&#xD;
          -  Recent use of antimicrobial agents, proton pump inhibitors, and H2 receptor blockers&#xD;
             within 1 month&#xD;
&#xD;
          -  Patients with gastric malignancy or who underwent previous gastric surgery&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Patients with major concomitant diseases, including psychic disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yumna M Shekeban, BSc</last_name>
    <phone>01289990938</phone>
    <phone_ext>+20</phone_ext>
    <email>Yumna.shekeban@alexu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noha A Hamdy, PhD</last_name>
    <email>noha.alaaeldine@alexu.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alexandria University outpatient clinics</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yumna M Shekeban, BSc</last_name>
      <phone>01289990938</phone>
      <phone_ext>+20</phone_ext>
      <email>Yumna.shekeban@alexu.edu.eg</email>
    </contact>
    <investigator>
      <last_name>Mai M Helmy, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shwikar M AbdElSalam, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Doaa A Header, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noha A Hamdy, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yumna M Shekeban, BSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 7, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 7, 2022</last_update_submitted>
  <last_update_submitted_qc>November 7, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Yumna Mohamed Shekeban</investigator_full_name>
    <investigator_title>Teaching Assistant at clinical pharmacy and pharmacy practice department, faculty of pharmacy Alexandria University</investigator_title>
  </responsible_party>
  <keyword>Helicobacter Pylori</keyword>
  <keyword>vonoprazan</keyword>
  <keyword>standard triple therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

